Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Ann E. Weber

Scott D. Edmondson

Jinyou Xu

Dooseop Kim

Malcolm Maccoss

Michael H. Fisher

Emma R. Parmee

Ann E Weber

Tesfaye Biftu

Emma R Parmee

Danqing D Feng

Michael H Fisher

Scott D Edmondson

Robert J Mathvink

Jason M Cox

Wallace T Ashton

Hyun O Ok

Charles G Caldwell

Ping Chen

Elizabeth M Naylor

XiaoXia Qian

Joseph Leslie Duffy

Linda Brockunier

Gui-Bai Liang

William J Greenlee

Lihu Yang

Ying-Duo Gao

Thomas L Shih

Anthony Mastracchio

Arthur A Patchett

Suresh B Singh

William H Parsons

Frank W Bennett

Stephane L Bogen

Gabor Butora

Ian W Davies

Lingyan Wang

Vinay M Girijavallabhan

Ralph A Rivero

Liping Wang

Daljit S Dhanoa

Quang T Truong

Angela Dawn Kerekes

Vincent Colandrea

Yuhua Huang

Bart Harper

Chan-Hwa Kuo

Hong Dong Chu

Brian Kirk

Hong Dong

Giovanna Scapin

David Earl Kaelin, Jr

Dong Ok

Leah Bitalac Reigle

Samuel Tolman

Xiaoxia Qian

Michael Fisher

Thomas A Halgren

Danqing Dennis Feng

Suresh Singh

The present invention relates to 2'-Alkynyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2, R3 and R4 are as defined herein. The present invention also relates to compositions comprising at least one 2&#x2032;-Alkynyl Substituted Nucleoside Derivative, and methods of using the 2&#x2032;-Alkynyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient. 

2'-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes

The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-&#xcf;V enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes

The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes

The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DPP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. 

Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

Growing community of inventors

Scotch Plains, NJ, United States of America

Ann E Weber